PANBELA THERAPEUTICS, INC.
SNBP evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Lead Asset:
- eflornithine (Phase 2)
What it means
What to watch
Prepared research question
What matters most for SNBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2024.
Tracking 3 pipeline candidates · 1 clinical trial for PANBELA THERAPEUTICS, INC..
Run PANBELA THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PANBELA THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$7M
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is PANBELA THERAPEUTICS, INC.'s lead drug candidate?
PANBELA THERAPEUTICS, INC.'s most advanced tracked candidate is eflornithine (Phase 2) for Gastric cancer, Type 1 diabetes, metastatic castration-resistant prostate cancer, NSCLC (STK11 mutation).
Who is the CEO of PANBELA THERAPEUTICS, INC.?
Jennifer K. Simpson Ph is the chief executive officer of PANBELA THERAPEUTICS, INC. (SNBP).
What therapeutic areas does PANBELA THERAPEUTICS, INC. focus on?
PANBELA THERAPEUTICS, INC. develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.